Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
about
Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 ProteaseTransmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databaseEvolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell countsThe replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsMutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.Update on human immunodeficiency virus (HIV)-2 infection.An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Higher HIV RNA Viral Load in Recent Patients with Symptomatic Acute HIV Infection in Lyon University Hospitals.Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.Protective immunity against HIV infection: lessons from HIV-2 infection.Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.Mortality and survival patterns of people living with HIV-2Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.Population mobility and the changing epidemics of HIV-2 in Portugal.Race and CD4+T-cell count in HIV prognosis and treatment
P2860
Q27652399-34A2FF95-2025-4E57-AF87-1AC9C3F3C4E6Q33321434-55B8A73F-EB7B-4DF2-93C0-9BABFFC7EAFAQ33591409-DFC92415-BA39-49A3-BDCD-AEC37C175DDBQ33593237-B4A03186-0BCE-4783-9483-94393CA9944EQ33705170-D09C186A-846C-419F-8F15-E425EB4B0A56Q33884059-7B485ED3-7752-4962-9A51-77E1E44630FFQ33963958-834BC478-735C-4B5A-AC19-76B15118C49EQ34041529-685FEBF3-CB40-49D2-B8B2-84929D0FE250Q34290973-94139DAE-5844-4F4A-8B8F-972341B42E31Q34387349-4CEAA379-8927-47EA-BD23-072DDEE51478Q34742090-6F9E66F2-24C6-4540-BA57-29C61F157009Q34992731-4CAB1EE6-FEDF-4884-ADF3-41497CE466F4Q35019924-B52AA082-15FC-4884-AAAC-DCFEE379A2A5Q35273824-2A37D119-D361-418B-8A28-A199EFD7F2EFQ35901205-0D6895D8-55B1-400D-B7EC-D9687AC64A79Q36747463-C8594925-0ADF-4302-BE1D-CAE2B6619E95Q36895619-7C83BAFD-F2FF-4B19-8C65-2007ADF54725Q36897863-227448DB-0225-45EE-9305-7487A05BCCA3Q37026564-0E47EFCF-4539-4888-B50B-BEA38B5066ACQ37083896-38847F48-32AF-4E1A-900B-06800A4158CAQ37307096-EB1F3FE8-25A1-4C39-9B44-B77567801526Q37365618-D99D99D3-CDC0-4E7F-BF1B-8B371589ADA6Q38538043-B02A180F-CEFA-445D-87EE-0520BF3D204EQ38682063-9A2B957E-0DF9-47A0-86C6-873F5E3C542DQ38820118-B6F69C85-A6A6-4857-8D5E-F35260048BE7Q38851677-A6C42DE0-3491-4176-AC8B-8F51BCEDAE13Q39448439-C17A6C05-D0E7-4EA4-B8AB-0C99928EE986Q41156500-9AA1126F-4408-45D5-9434-C117D72A191AQ42318282-272A89A1-54EF-4886-8BCF-CFB01F4EF696Q44990505-10E13641-BE97-46B1-B5E4-5EF5FEF0C650Q45032977-C38B79F7-542C-4B67-9878-F3DDB2C2B691Q46320704-4A429258-9697-4341-937C-FBF6D23FF3A2Q58033132-C24EA850-4F24-4B2A-849C-D18781E5EC36
P2860
Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Factors associated with clinic ...... ients: the French ANRS cohort.
@en
Factors associated with clinic ...... ients: the French ANRS cohort.
@nl
type
label
Factors associated with clinic ...... ients: the French ANRS cohort.
@en
Factors associated with clinic ...... ients: the French ANRS cohort.
@nl
prefLabel
Factors associated with clinic ...... ients: the French ANRS cohort.
@en
Factors associated with clinic ...... ients: the French ANRS cohort.
@nl
P2093
P1433
P1476
Factors associated with clinic ...... ients: the French ANRS cohort.
@en
P2093
Annie Leprêtre
François Simon
Françoise Brun-Vezinet
French HIV-2 Cohort Study Group
Genevieve Chêne
Pauline Campa
Roger Salamon
Sophie Matheron
Sophie Pueyo
P304
P356
10.1097/00002030-200312050-00006
P407
P577
2003-12-01T00:00:00Z